Michel Versluis is a Full Professor at the University of Twente, Netherlands, specializing in Physical and Medical Acoustics within the Physics of Fluids group. His work focuses on microbubbles and microdroplets for medical imaging and therapy, as well as microfluidic applications in medicine and nanotechnology. University of Twente, Physics of Fluids group His research bridges physics and biomedical engineering, with publications in high-impact journals like PNAS and IEEE Transactions. Recent work emphasizes ultrasound-driven microbubble dynamics, additive manufacturing of flow phantoms, and deep learning for super-resolution imaging. 2025 publications: vascular phantoms, PROTEUS simulator, acoustic microbubble control 2024 innovations: 3D-printed medical devices, immunogenic cell death optimization Contact: m.versluis@utwente.nl
Gustavo Nader, Ph.D., is a Professor of Kinesiology at The Pennsylvania State University's College of Health and Human Development, where he holds the Dorothy Foehr Huck and J. Loyd Huck Endowed Chair in Molecular, Cellular and Integrative Physiology. His research laboratory at 101 Noll Lab focuses on molecular mechanisms of skeletal muscle adaptation, employing human, animal, and cellular models to investigate ribosome biogenesis, transcriptional regulation, and muscle growth control in contexts ranging from exercise hypertrophy to cancer cachexia. Dr. Nader's research examines fundamental processes including: Ribosome biogenesis and its role in muscle growth regulation Epigenetic control of RNA Polymerase I activity Molecular pathways in mechanical overload-induced hypertrophy Tumor-induced muscle wasting mechanisms Biomimicry approaches inspired by hibernator physiology His work spans exercise physiology, cancer biology, and environmental stress responses. Analysis of his 15 most recent publications (2015-2025) reveals predominant themes in muscle hypertrophy mechanisms, cancer cachexia pathophysiology, ribosomal function analysis, and environmental stress impacts on muscle. His work consistently integrates molecular techniques with physiological models across species. Notable scientific recognitions include: Dorothy Foehr Huck and J. Loyd Huck Chair appointment (2024) Huck Institutes Leadership Fellowship (2025-2026) Dr. Nader leads an active research team investigating muscle plasticity, with current projects funded through the Huck Institutes of the Life Sciences. He collaborates extensively through Penn State's Integrative and Biomedical Physiology graduate program and Center for Cellular Dynamics.
Dr. Julia Kamenz is an Assistant Professor (Rosalind Franklin fellow) at the University of Groningen's Faculty of Science and Engineering, where she leads research in the Molecular Systems Biology group within the Groningen Biomolecular Sciences and Biotechnology Institute (GBB). Her work focuses on understanding the molecular mechanisms that regulate cell cycle progression and cell division. Dr. Kamenz received her undergraduate training in Biochemistry at the University of Tuebingen, completed her PhD at the Friedrich Miescher Laboratory of the Max Planck Society under Dr. Silke Hauf (defended February 2015 with highest honors), and conducted postdoctoral research at Stanford University with Prof. James E. Ferrell. Her PhD work was supported by a Boehringer Ingelheim Fonds fellowship, and her postdoc was funded by a German Research Foundation (DFG) Postdoctoral Fellowship. Her research expertise spans cell cycle regulation and dynamics, post-translational modifications, Xenopus laevis model systems, and live cell microscopy. Dr. Kamenz investigates how kinases and phosphatases intricately regulate cell proliferation and division, with particular interest in the molecular mechanisms that ensure faithful chromosome segregation during mitosis. Her recent work has revealed novel insights into mitotic checkpoint signaling, particularly in early embryonic development where these checkpoints appear to function differently than in somatic cells. Dr. Kamenz's publication record demonstrates a strong focus on the dynamics of cell cycle transitions, with recent papers appearing in high-impact journals including Nature, The Journal of Biological Chemistry, and The Journal of Cell Biology. Her research integrates experimental biochemistry, live-cell imaging, and computational modeling approaches to understand complex regulatory networks. ERC Starting Grant (November 2022) NWO Vidi Grant (July 2021) Mansour Postdoctoral Travel Award (2019) Dr. Kamenz has secured significant research funding including an ERC Starting Grant (€1.5 million) and an NWO XS grant (€50,000) for her project "What limits mitotic checkpoint signaling in the early embryo?" Her research contributes to understanding fundamental biological processes with implications for developmental biology and cancer research. She collaborates extensively within the University of Groningen and with international partners, particularly in the areas of cell cycle research and biophysical approaches to biological problems. Dr. Kamenz leads a research group focused on cell cycle regulation within the Molecular Systems Biology division of the Groningen Biomolecular Sciences and Biotechnology Institute. Her lab combines biochemical approaches using Xenopus egg extracts with live-cell imaging and computational modeling to dissect the molecular mechanisms controlling cell division.
Prof. Casper Hoogenraad is a full professor in Molecular Neuroscience at the Department of Cell Biology, Faculty of Science, Utrecht University. His research focuses on understanding how intracellular protein trafficking underlies neuronal development and function, with particular emphasis on the microtubule cytoskeleton, synaptic cargo trafficking, and synaptic plasticity. He leads an active research group within Utrecht University's Cell Biology department and collaborates extensively with other neuroscience research groups. Education: PhD, Erasmus University Rotterdam (1996-2001) Postdoc, Massachusetts Institute of Technology (2002-2005) Hoogenraad's research spans three main themes: cytoskeleton dynamics during neurodevelopment and synaptic plasticity, motor proteins and adaptors as regulators of synaptic transport, and psychiatric and neurologic disease disorders linked to intracellular transport. His work combines genetics, biochemistry, molecular, and cellular biology methods in in vitro (neuron cultures), ex vivo (brain slices), and in vivo (mice) systems, along with advanced microscopy techniques including immunofluorescent confocal microscopy, high-resolution live cell imaging, and photo-activated localization microscopy (PALM). Analysis of Hoogenraad's recent publications reveals a strong focus on microtubule organization, neuronal polarity, and the molecular mechanisms underlying synaptic function and dysfunction. His work frequently explores how disruptions in intracellular transport contribute to neurological disorders including Alzheimer's disease, schizophrenia, and autism spectrum disorders, with particular attention to the relationship between cytoskeletal organization and cargo transport in neuronal compartments. Scientific Awards and Memberships: ZonMW-VIDI (2004) European Young Investigators (EURYI) award (2005) NWO-ALW VICI (2011) ERC Consolidator grants (2013) FENS-Kavli Network of Excellence (2014) European Molecular Biology Organization (EMBO) (2015) Young Academy of Europe (YAE) (2015) IBRO Kemali Prize (2016) Hoogenraad leads a research group studying neuronal development and function, with a particular focus on how intracellular transport mechanisms contribute to both normal brain function and neurological disorders. His laboratory employs a multidisciplinary approach combining molecular, cellular, and systems neuroscience techniques to investigate the molecular basis of neuronal polarity, synaptic plasticity, and the pathogenesis of neurological disorders. He has secured significant research funding through prestigious grants including ERC Consolidator grants. The Hoogenraad lab operates within the Cell Biology department at Utrecht University, collaborating with other research groups focusing on cellular dynamics, biophysics, and neurobiology. The lab utilizes advanced microscopy techniques including immunofluorescent confocal microscopy, high-resolution live cell imaging (spinning disc microscopy and total internal reflection fluorescence microscopy), and quantitative analysis using advanced high-resolution microscopy (photo-activated localization microscopy). Current lab technicians include Phebe Wulf and Bart de Haan.
Prof. Dr. Tunç ÇATAL is a Professor of Molecular Biology and Genetics at Üsküdar Üniversitesi. He holds a PhD from İstanbul Technical University (2008) and conducted postdoctoral research at Oregon State University and the National University of Ireland Galway. His expertise spans microbial biotechnology, molecular biology, and hydrogen production. Education: BSc in Biology, İstanbul University (2001) MSc in Biology, İstanbul University (2004) PhD in Molecular Biology-Genetics and Biotechnology, İstanbul Technical University (2008) Administrative Roles: Head of Molecular Biology and Genetics Department (English Program) Director of PROMER Research Center Bologna Coordinator and Erasmus Coordinator His research focuses on microbial electrochemical systems, bioremediation, and bioenergy. Notable contributions include optimizing hydrogen production using microbial electrolysis cells and studying the effects of pharmaceuticals on microbial fuel cell efficiency. He has supervised 3 graduate theses and holds TÜBİTAK awards for impactful publications. His work integrates environmental science and molecular biology, with applications in sustainable energy (e.g., hydrogen production) and wastewater treatment. Recent studies explore novel curcumin compounds for toxicity mitigation and marine mucilage-based bioelectrochemical systems.
Caitriona M. O'Driscoll is Professor and Chair of Pharmaceutics at University College Cork's School of Pharmacy, Ireland. With over four decades of academic experience, she previously served as Head of the School of Pharmacy at UCC from 2003-2009 and 2010-2013. Her established drug delivery research team spans from pre-formulation through to production and manufacture of prototype delivery systems suitable for clinical trial, with strong industry links underpinning many research projects. Her research interests focus on translational drug delivery with emphasis on 'problem' drugs including poorly water soluble compounds and biopharmaceuticals like peptide/protein drugs, plasma DNA and siRNA. She develops nano-sized delivery constructs that are robust enough to survive processing, stable on storage, and achieve cell/site specific delivery in vivo. Greater than 40% of new chemical entities are poorly water soluble Biopharmaceuticals now approach 50% of all new drugs in development Major barrier is design of efficient delivery systems Special focus on oral drug delivery despite challenges Analysis of her recent publications reveals a strong emphasis on targeted nanodelivery systems for cancer therapy, particularly prostate and colorectal cancer, as well as neurodegenerative diseases like Huntington's. Her work demonstrates expertise in cyclodextrin-based nanoparticles, siRNA delivery, and disease-specific formulations that account for conditions like Crohn's disease that affect drug delivery. Scientific awards include: 'Person of the Year award' by Parenteral Drug Association (Ireland Chapter) in 2013 'Award for Professional Excellence' by Helix Health in 2007/2008 'Award for Pharmacist of the Year' by Helix Health in 2007/2008 With €10.5M in career research income and 25 PhDs graduated, Professor O'Driscoll's work has attracted funding from diverse sources including Science Foundation Ireland, Enterprise Ireland, and industry partners. Her research group maintains strong links with Pharmaceutical Chemistry and Process & Chemical Engineering at UCC, creating a unique strength for drug development research from design through to clinical trial. She has served as external examiner for multiple universities and as PhD thesis examiner at institutions worldwide. Her research team operates within UCC's drug delivery group, which has established expertise spanning from pre-formulation through to production and manufacture of prototype delivery systems. The group maintains strong industry connections and offers various PhD positions, focusing particularly on translational research with product-driven applications.
Martin Gosau is a Professor at the Clinic and Polyclinic for Oral and Maxillofacial Surgery within the Medical Faculty of the University Medical Center Hamburg-Eppendorf (UKE). His research focuses on Oral Surgery , Maxillofacial Surgery , and Regenerative Medicine , with a strong emphasis on Dental Implants , Head and Neck Cancer , and Oral Pathology . University: University Medical Center Hamburg-Eppendorf School: Medical Faculty Department: Oral and Maxillofacial Surgery Academic Rank: Professor His recent work explores: Oral Health in Genetic Disorders (e.g., hypophosphatasia) Advanced Surgical Techniques (e.g., nanosecond lasers, fluorescence angiography) Biomaterials and Tissue Engineering (e.g., silk fibroin membranes, extracellular vesicles) Cancer Prognostics (e.g., DCBLD1 overexpression in HNSCC) Key trends in his 15 most recent articles include applications of machine learning in oral diagnostics, stem cell research for bone regeneration, and biomaterials in reconstructive surgery. He frequently collaborates with Ralf Smeets and Thomas Vollkommer , with publications spanning Frontiers in Immunology , Oral Surgery , and Scientific Reports .
Lara A. Estroff is a Full Professor and the current Chair of the Department of Materials Science and Engineering at Cornell University's College of Engineering. She has been a faculty member since 2005 and served as Director of Graduate Studies from 2015 to 2019. Her academic leadership and research excellence position her at the forefront of bio-inspired materials and biomineralization research. Her educational background includes a B.A. in Chemistry from Swarthmore College (1997) and a Ph.D. in Chemistry from Yale University (2003), followed by an NIH-funded postdoctoral fellowship at Harvard University in the lab of Prof. George M. Whitesides. Dr. Estroff's research centers on the fundamental mechanisms of crystal growth, biomineralization, and pathological mineralization. She investigates how organisms control mineral formation and applies these principles to engineer synthetic materials with complex structures and functionalities. Her work spans biomaterials, tissue engineering, and energy materials—particularly hybrid organic-inorganic perovskites for photovoltaics. She employs advanced characterization techniques and has pioneered in situ methods to monitor crystallization dynamics. Her recent publications reveal a strong trend toward interdisciplinary research, integrating materials science with cancer biology, immunology, and machine learning. The articles emphasize bio-inspired synthesis, mineral-tissue interactions, and the development of functional crystalline materials for medical and energy applications. Faculty Early CAREER Award, National Science Foundation (2009) Fiona Ip Li '78 and Donald Li '75 Excellence in Teaching Award, Cornell College of Engineering (2007) Marilyn Emmons Williams Award, Cornell Undergraduate Research Board (2009) Keynote Speaker, Gordon Research Seminar on Biomineralization (2012) Lawrence Berkeley National Lab Affiliate (2013) Dr. Estroff leads a major DOE-funded project titled “Formulation Engineering of Energy Materials via Multiscale Learning Spirals,” a $3 million, three-year initiative using machine learning to optimize perovskite synthesis for solar cells. She has advised numerous graduate students and postdoctoral researchers, and her lab is known for fostering collaborative, cross-disciplinary research. She has also contributed to educational initiatives at Cornell, particularly in undergraduate research and materials education. Her research group operates at the intersection of chemistry, engineering, and biology, focusing on high-resolution characterization of biominerals, in situ crystal growth studies, and the design of in vitro models for cell-mineral interactions. The lab actively collaborates with institutions including Lawrence Livermore National Laboratory, National Renewable Energy Laboratory, and Johns Hopkins University.
John Capobianco, PhD, is a Professor in the Department of Chemistry and Biochemistry at Concordia University and holds the Honorary Concordia University Research Chair in Nanoscience. His research focuses on lanthanide-doped nanoparticles, upconversion luminescence, and biomedical applications. PhD, University of Geneva Key research areas include: Nanomaterials synthesis and spectroscopy Upconversion for biomedical imaging Drug delivery systems Photodynamic therapy for cancer treatment Optical thermometry and sensing Recent publications highlight advancements in: X-ray detection via photochromic nanoparticles Lipid-coated nanoparticles for lung permeation Cooperative energy transfer in Yb3+/Eu3+ complexes Biocompatible nanomaterials for secure information storage Pr3+-doped radiosensitizers for glioblastoma therapy Scientific recognitions: Honorary Concordia University Research Chair in Nanoscience Teaching includes undergraduate and graduate courses in inorganic chemistry and spectroscopy. His work bridges fundamental material science with applied biomedical engineering, emphasizing optical properties and therapeutic applications of lanthanide-based nanomaterials.
Professor Mirko Trajkovski leads the Laboratory of Metabolic Diseases at the Faculty of Medicine, University of Geneva. He completed his PhD at the International Max Planck School in Dresden (2005), followed by postdoctoral research at ETH Zurich, before establishing his lab at University College London (2012) and moving to Geneva (2013). His work focuses on adipose tissue plasticity , gut microbiota , and their roles in obesity , diabetes , and insulin resistance . Swiss National Science Foundation Professor (2014) ERC Starting Grant (2014) & Consolidator Grant (2019) Dr Walter Seipp Prize & Carl Gustav Carus Prize (2005) His lab investigates fat browning mechanisms , microbiota-host communication , and multi-tissue metabolic regulation using in vivo , in vitro , and human cohort approaches. Recent publications emphasize microbiome-based therapies , temperature effects on metabolism , and gut-bone-adipose crosstalk . Current advisees include PhD student Silas Kieser, with past members like Jing Xue, Salvatore Fabbiano, and Claire Chevalier contributing to immuno-metabolism and microbial engineering projects.
Kelsey Swingle is an Assistant Professor of Bioengineering at Rice University, where she leads the Swingle Lab at the intersection of biomaterials science, immune engineering, and reproductive biology. Her research focuses on engineering therapeutic and vaccine technologies with translational potential. Ph.D. in Bioengineering from the University of Pennsylvania B.S.E. in Biomedical Engineering from Case Western Reserve University Dr. Swingle’s research explores the design of lipid nanoparticles (LNPs) and nucleic acid therapeutics for women’s health applications, including pre-eclampsia, preterm birth, and gynecologic cancers. Her work integrates bioengineering principles with immune modulation strategies to develop targeted therapies. The trends in her publications highlight advancements in LNP elasticity optimization for placental mRNA delivery, targeted systemic RNA delivery to the brain, and in utero gene editing applications. Her lab prioritizes interdisciplinary approaches to overcome biological barriers in women’s health. 2025 Solomon R. Pollack Award for Excellence in Graduate Bioengineering Research 2024 Muriel Joan Drew Hege Award for Women in Cellular Immunotherapy Research 2024 Penn Engineering Outstanding Teaching Award 2023 Gordon Research Conference Travel Award 2022 Society for Biomaterials STAR Award 2020 NSF Graduate Research Fellowship The Swingle Lab collaborates with the Texas Medical Center to develop precision nanomedicines. Her team employs in vitro, ex vivo, and in vivo models to study biomaterial interactions with female-specific tissues, emphasizing translational research and inclusive scientific communication.
John Diffley is a Principal Group Leader and Associate Research Director at The Francis Crick Institute in London, UK, where he leads research on DNA replication mechanisms. His work focuses on understanding how cells precisely duplicate their DNA during cell division and how errors in this process contribute to cancer development. Diffley obtained his PhD from New York University in 1985 and completed postdoctoral training with Bruce Stillman at Cold Spring Harbor Laboratory until 1990. He established his research group at the Clare Hall Laboratories (originally Imperial Cancer Research Fund, then Cancer Research UK) before moving to The Francis Crick Institute in 2015. His research spans DNA replication initiation, cell cycle control, replication fork checkpoints, and epigenetic inheritance. Diffley's lab has pioneered methods to reconstitute chromatin replication using purified proteins, providing unprecedented insights into chromosome biology. His team combines genetics, cell biology, and biochemistry to study the molecular 'machines' that copy DNA in yeast and human cells. Analysis of Diffley's recent publications reveals a strong focus on structural mechanisms of DNA replication, particularly using cryo-EM to visualize replication machinery. His work examines helicase loading and activation, replication fork stability under stress, and the connection between replication errors and cancer development. The research spans model organisms to human cells, with increasing emphasis on structural approaches in recent years. FRS (Fellow of the Royal Society) FMedSci (Fellow of the Academy of Medical Sciences) Diffley actively mentors a diverse team of postdoctoral researchers and PhD students, investigating various aspects of DNA replication. His lab has received substantial funding to support their work on replication mechanisms, with projects spanning basic biochemical reconstitution to studies of replication errors in cancer contexts. The lab maintains multiple technical platforms including structural biology, biochemistry, and cell biology approaches. His research group operates within The Francis Crick Institute's collaborative environment, utilizing shared facilities for structural biology, microscopy, and genomics to advance understanding of DNA replication mechanisms and their implications for genome stability and disease.
Steven R. Caliari is an Associate Professor in the Department of Chemical Engineering with a secondary appointment in Biomedical Engineering at the University of Virginia’s School of Engineering and Applied Science. He serves as the ChE Graduate Program Director and is a SEAS Copenhaver Fellow (2023). His research focuses on designing biomaterials to study cell-microenvironment interactions, addressing challenges in disease and tissue engineering. He holds a B.S. (2007, University of Florida), M.S. (2010), and Ph.D. (2013) in Chemical Engineering from the University of Illinois, followed by an NIH postdoctoral fellowship at the University of Pennsylvania. His research interests include biomaterials, mechanobiology, musculoskeletal tissue engineering, and advanced manufacturing for biological applications. His lab has pioneered viscoelastic hydrogel platforms and conductive collagen scaffolds, supported by NIH, NSF, DoD, and industry grants. Notable awards include the NSF CAREER Award (2021) and NIH MIRA (2020). Grants: NIH (NIGMS), NSF CAREER, V Foundation, UVA-Coulter Partnership Courses: Tissue Engineering (BME/CHE 4417), Transport Processes I (CHE 3321) Labs: Caliari Lab focuses on biomaterial design and mechanobiological studies His work bridges fundamental science and translational applications, emphasizing dynamic material systems for regenerative medicine and disease modeling.
Prof. Dr. Soeren Lienkamp is an Assistant Professor at the Institute of Anatomy , Faculty of Medicine , University of Zurich . His work bridges digital education and genetic research , focusing on enhancing medical teaching through innovative formats. Research Interests : Genetics, developmental biology, kidney disease modeling, CRISPR applications, digital medical education, and advanced microscopy. Methodologies : Combines Xenopus tropicalis models, deep learning , and bioengineering to study genetic kidney disorders and improve diagnostic tools. Publication Trends : His recent articles highlight predictable genome editing , 3D imaging technologies , and mechanistic insights into kidney and eye development. Earlier works focus on ciliary function , Wnt signaling , and metabolic stress in renal cells.
Kuo-Ching Mei is an Assistant Professor of Molecular Pharmaceutics in the College of Pharmacy at the University of Utah. His laboratory pioneers lipid nanoparticle (LNP)-based gene delivery platforms that span cancer immunotherapy, immune tolerance induction, and programmable nanomedicine. Education B.Sc., Taipei Medical University Ph.D., University of London Dr. Mei’s research integrates molecular pharmaceutics, immunoengineering, and translational pharmaceutical sciences to advance precision immunotherapies. Core themes include mRNA-LNP systems for both immunostimulatory (anti-cancer vaccines) and immunomodulatory (tolerogenic) applications, the influence of immunometabolic cues (IFN-γ, amino-acid deprivation) on RNA translation, and the development of next-generation lipid chemistries for organ- and cell-specific delivery. Across his recent publications, a clear trend emerges toward refining LNP composition and architecture to enhance RNA delivery specificity, minimize toxicity, and modulate innate and adaptive immunity. Studies range from fundamental formulation science to pre-clinical evaluation in syngeneic tumor models and assessments of anti-vector immune responses. Research Support & Collaborations While specific grant numbers are not listed, the breadth and continuity of projects—from programmable lipid synthesis to high-throughput in vivo screening—indicate robust funding and active interdisciplinary collaborations within the University of Utah’s bioscience ecosystem. Laboratory & Team Dr. Mei leads a dynamic lab that employs chemical synthesis, formulation development, high-throughput screening, and integrated in vitro/in vivo disease models to translate discoveries into clinically viable RNA therapeutics and immunoengineering solutions.
